DEFOROLIMUS API AND TABLET SUPPLY AGREEMENTDeforolimus Api and Tablet Supply Agreement • August 11th, 2008 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS DEFOROLIMUS API AND TABLET SUPPLY AGREEMENT (“Agreement”), is made and entered into as of May 7, 2008 (the “Effective Date”) by and among ARIAD Pharmaceuticals, Inc. and ARIAD Gene Therapeutics, Inc., both Delaware corporations with a principal place of business at 26 Landsdowne Street, Cambridge, Massachusetts 02139 (collectively, “ARIAD”), Merck & Co., Inc., a company organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, New Jersey, 08889-01000, (“MERCK Parent”) and Merck and Company Incorporated, a company organized under the laws of Delaware with offices at 5307 Limestone Road, Suite 200, Wilmington, Delaware 19808 ("MACI" and, collectively with MERCK Parent, "MERCK"). ARIAD and MERCK are each hereafter referred to individually as a “Party” and together as the “Parties.”
